selected scholarly activity
-
academic article
- The Prevalence and Risk for Herpes Zoster Infection in Adult Patients With Diabetes Mellitus in the Canadian Primary Care Sentinel Surveillance Network.. Canadian Journal of Diabetes. 42:465-469. 2018
- Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials.. Canadian Journal of Clinical Pharmacology. 24:e32-e40. 2017
- Lack of Health-Related Quality of Life and Patient-Centred Outcome Measures in Randomized Controlled Trials Conducted for Diabetes Pharmacotherapy: SGLT-2 Receptor Inhibitors as An Example.. Canadian Journal of Clinical Pharmacology. 24:e1-e14. 2017
- Sulfonylurea and the Heart: Theoretically a Compounded Question from a Pathophysiological Perspective.. Canadian Journal of Clinical Pharmacology. 23:e193-e195. 2016
- A Systematic Review of Clinical Practice Guidelines' Recommendations on Levothyroxine Therapy Alone versus Combination Therapy (LT4 plus LT3) for Hypothyroidism.. Clinical and Investigative Medicine. 38:E305-E313. 2015
- Sex/Gender-Based Pharmacology and Statin Utilization Amongst Elderly Patients with Diabetes.. Clinical and Investigative Medicine. 38:E371-E383. 2015
- Challenges in pharmacotherapeutics education for diabetes in real-world clinical settings: views from family medicine and internal medicine residents.. Clinical and Investigative Medicine. 38:E73-E81. 2015
- Thyroid stimulating hormone suppression post-therapy in patients with Graves' disease: a systematic review of pathophysiology and clinical data.. Clinical and Investigative Medicine. 38:E31-E44. 2015
- Exploring the Distribution of Prescription for Sulfonylureas in Patients with Type 2 Diabetes According to Cardiovascular Risk Factors Within a Canadian Primary Care Setting.. Canadian Journal of Clinical Pharmacology. 22:e228-e236. 2015
- Thyroid Stimulating Hormone Suppression Post-Therapy in Patients with Graves' Disease: A Systematic Review of Pathophysiology and Clinical Data. Clinical and Investigative Medicine. 38:131-144. 2015
- Personalized pharmacotherapy in diabetes care using clinical pharmacology data of basal insulin analogues.. Expert Review of Clinical Pharmacology. 7:451-455. 2014
- Sex/gender disparities in randomized controlled trials of statins: the impact of awareness efforts.. Clinical and Investigative Medicine. 37:E163. 2014
- Household income and LDL-C goal attainment in patients with diabetes and dyslipidemia in a Canadian dataset.. Clinical and Investigative Medicine. 37:E47-E52. 2014
- Goal attainment for multiple cardiovascular risk factors in community-based clinical practice (a Canadian experience).. Journal of Evaluation in Clinical Practice. 15:212-216. 2009
- Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension.. Journal of Clinical Epidemiology. 60:1-7. 2007
- Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care.. Clinical and Investigative Medicine. 30:E63-E69. 2007
- A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics.. Journal of Evaluation in Clinical Practice. 12:463-470. 2006
- Pharmacovigilance in a genomic era.. Pharmacogenomics Journal. 6:158-161. 2006
- Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.. Canadian Journal of Clinical Pharmacology. 12:e254-e263. 2005
-
conference paper
- Exploring the distribution of cardiovascular disease and risk factors amongst patients with diabetes on sulfonylurea in a Canadian primary care dataset. Diabetologia. S433-S434. 2015
- Gender Differences for High Potency Statin Utilization amongst Elderly Patients with Diabetes in Ontario, Canada. Diabetes. A181-A181. 2015
- Ten-Year Trends in Utilization of Bioequivalent Doses of Statin amongst Elderly Patients with Diabetes. Diabetes. A177-A177. 2015
- Gender Gap for LDL-C Goal Achievement Amongst Patients with Diabetes and Dyslipidemia. Endocrine Reviews Recent Progress in Hormone Research. 2014
- Previous Exposure to Statin and Adherence to Lipid-Lowering Therapeutics. Endocrine Reviews Recent Progress in Hormone Research. 2014
- The Influence of Household Income on Therapeutic Goal Achievement in Diabetic Patients in the Canadian Healthcare System. Diabetes. A315-A315. 2012
- Application of Principals of Pharmacoepidemiology, Clinical Pharmacology and Therapeutics in Pharmacoeconomics. Pharmacoepidemiology and Drug Safety. S148-S148. 2009
- Significance of Incorporating Real World Clinical Non-Adherence and Drug Adverse Events Data into Pharmacoeconomic Models: Statins Example. Pharmacoepidemiology and Drug Safety. S192-S192. 2009
- EVIDENCE-BASED TIME HORIZON FOR THE INTERVENTIONS IN PHARMACOECONOMIC MODELS. Value in Health. A6-A6. 2009
- SIGNIFICANCE OF INCORPORATING COMMUNITY-BASED DATA OF A TARGET POPULATION INTO PHARMACOECONOMIC MODELS. Value in Health. A21-A21. 2009
- The Effect of Metabolic Syndrome on Global Cardiovascular Risk Reduction in High-Risk Patients with Dyslipidemia on Pharmacotherapy. Circulation. E343-E343. 2009
- APPLICATION OF CLINICAL PHARMACOLOGY IN PHARMACOECONOMICS: A SYSTEMATIC REVIEW ON THE ECONOMIC EVALUATIONS OF STATINS. Clinical Pharmacology and Therapeutics. S18-S18. 2009
- Cardiovascular event driven economic analysis of rosuvastatin versus simvastatin using pragmatic head-to-head RCTs with surrogate end-point measures. Value in Health. A194-A194. 2008
- Application of clinical pharmacology in pharmacoeconomics: Cost-effectiveness analysis of therapeutics using clinically equivalent doses: An example from HMG-COA reductase inhibitors (STATINS).. Clinical Pharmacology and Therapeutics. S76-S76. 2008
- Application of clinical pharmacology in pharmacoeconomics: Economic evaluation of HMG-COA reductase inhibitors using pragmatic head-to-head randomized controlled trials with up-titration of drug doses to obtain therapeutic targets for LDL-cholesterol.. Clinical Pharmacology and Therapeutics. S76-S76. 2008
- Exploring prognostic factors for achieving global cardiovascular risk reduction in high-risk patients with dyslipidemia and cardiometabolic syndrome on pharmacotherapy. Canadian Journal of Cardiology. 253C-253C. 2007
- Community-based global cardiovascular risk reduction with pharmacotherapy for modifiable risk factors in high-risk patients. Pharmacoepidemiology and Drug Safety. S200-S201. 2007
- Assessing metabolic syndrome in patients using lipid lowering therapeutics in the Canadian population.. Clinical Pharmacology and Therapeutics. S27-S28. 2007
- Potential problems in using RCT data to estimate cost-effectiveness: Results from an analysis of etanercept use in rheumatoid arthritis. Value in Health. A28-A29. 2005
- Mixed or dynamic trial design: New methodology of research for pharmacogenetics and pharmacogenomics studies.. Clinical Pharmacology and Therapeutics. P65-P65. 2005